Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients

BACKGROUND. Hodgkin lymphoma (HL) is characterized by the presence of CD30-positive Hodgkin Reed-Sternberg cells. Approximately 30%–40% of patients with advanced disease are refractory to frontline therapy or will relapse after first-line treatment. The standard management of these patients is salva...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Zinzani, Pier Luigi, Pellegrini, Cinzia, Cantonetti, Maria, Re, Alessandro, Pinto, Antonello, Pavone, Vincenzo, Rigacci, Luigi, Celli, Melania, Broccoli, Alessandro, Argnani, Lisa, Pulsoni, Alessandro
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2015
Aiheet:
Hematologic Malignancies
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4679088/
https://ncbi.nlm.nih.gov/pubmed/26500229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0227
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia